Intense acute phase response in ischemic patients

Kaźmierczak, Ewa; Sobieska, Magdalena; Kaźmierczak, M; Mrozikiewicz, A; Wiktorowicz, Krzysztof

doi:10.1016/s0167-5273(98)00340-4

Cited by 10 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less evidence is thus available about APPs behavior in patients with ACS. An intense APPs response has been reported by Kazmierczak et al [20] in ischemic patients while, in cases of ACS, APPs levels seem to be related to severity of ACS and coronary atherosclerosis [4]. Several cardiovascular risk factors, such as smoking, hypertension, cholesterol and diabetes, were associated with increased APPs levels [21], and APPs were reported to have a prognostic relevance in several subsets of patients.…”

Section: Discussionmentioning

confidence: 85%

Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction

Brunetti

Pellegrino

Cuculo

2007

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction

Brunetti

Pellegrino

Cuculo

2007

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

“…It is reported that a1-acid glycoprotein increases in HF patients [24]. Tolvaptan is bound not only to albumin but also to other proteins such as a1-acid glycoprotein.…”

Section: Discussionmentioning

confidence: 97%

The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study

Okabe

Yakushiji

Igawa

et al. 2015

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYBackground: Heart failure (HF) with hypoalbuminemia is associated with poor response to conventional therapy. We investigated whether tolvaptan, a potent aquaretic agent, might be of benefit in HF patients with hypoalbuminemia. Methods: We prospectively enrolled 40 patients hospitalized for HF. Patients received conventional therapy including loop diuretics. We subsequently added tolvaptan in the range of 3.75-15 mg daily and it was discontinued after improvement of HF symptoms. We compared clinical and laboratory data in HF patients with and without hypoalbuminemia (defined as serum albumin <3.0 g/ dL). Results: Tolvaptan was administered in 18 HF patients with hypoalbuminemia (Group A) and 22 HF patients without hypoalbuminemia (Group B). The mean serum albumin was 2.63 AE 0.27 and 3.46 AE 0.25 g/dL, respectively. The average urine output on tolvaptan increased significantly in both groups (1644.4 AE 797.6-3011.6 AE 1453.8 mL/day, P = 0.004; 1459 AE 612.7-2112.2 AE 724.5 mL/day, P = 0.008; respectively). In addition, we observed higher urine output on therapy in Group A than in Group B (P = 0.015). There was a moderate negative correlation between serum albumin and average urine output on tolvaptan (r = À0.42, P = 0.007). Conclusions: The addition of tolvaptan to low dose loop diuretics might be an effective strategy for treatment of HF patients with hypoalbuminemia.

show abstract

“…Kazmierczak et al [17] defined a significant rise of CRP concentrations in patients with AMI and UA, with different release curves; these authors split AMI patients with heart failure from those without heart failure.…”

Section: Discussionmentioning

confidence: 99%

C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings

Brunetti

Troccoli

Pellegrino

2006

International Journal of Cardiology

View full text Add to dashboard Cite

Intense acute phase response in ischemic patients

Cited by 10 publications

References 26 publications

Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction

Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction

The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study

C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings

Contact Info

Product

Resources

About